Faisal Ghiath Sukhtian insider trades: Outlook Therapeutics (OTLK) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Faisal reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | OTLK | ↑ Buy | 95,398 | $1.05 | $100K | Direct | Jul 29, 2026 (0d) |
| May 27, 2026 | OTLK | ↑ Buy | 122,174 | $0.41 | $50K | Direct | May 27, 2026 (0d) |
| Oct 7, 2022 | OTLK | ↑ Buy | 30,000 | $1.29 | $39K | Direct | Oct 11, 2022 (4d) |
| Dec 2, 2021 | OTLK | ↑ Buy | 18,000 | $1.40 | $25K | Direct | Dec 2, 2021 (0d) |
| Apr 19, 2021 | OTLK | ↑ Buy | 10,000 | $1.82 | $18K | Direct | Apr 20, 2021 (1d) |
| Sep 17, 2020 | OTLK | ↑ Buy | 10,000 | $0.67 | $7K | Direct | Sep 17, 2020 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other OTLK insiders
Open-market trades in the last 12 months
About Faisal Ghiath Sukhtian's insider trades
Faisal Ghiath Sukhtian is a director at Outlook Therapeutics (OTLK). Since Sep 17, 2020, Faisal has reported 6 open-market purchases worth $239K and no sales on SEC Form 4. In the last 12 months: 2 buys ($150K).
Their filings also include grants and awards (19 filings), other transactions (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OTLK insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.